List of Excipients in Branded Drug PREDNISONE

Generic Drugs Containing PREDNISONE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	prednisone	0054-4741	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	prednisone	0054-4741	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	prednisone	0054-4741	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	prednisone	0054-4741	SODIUM STARCH GLYCOLATE TYPE A POTATO
Hikma Pharmaceuticals USA Inc	prednisone	0054-4741	STARCH, CORN

What are the Most Frequently-Used Excipients in PREDNISONE?

# Of NDCs	Excipient
2	ALCOHOL
22	ALUMINUM OXIDE
85	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
271	CELLULOSE, MICROCRYSTALLINE

Prednisone Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Prednisone is a mature, low-cost corticosteroid with limited active-ingredient patent protection and intense generic competition. Commercial opportunity is concentrated in differentiated oral delivery: lactose-free tablets, pediatric liquids, orally disintegrating tablets, taste-masked suspensions, dose-flexible products, and chronotherapy-oriented delayed-release formulations. The strongest commercial strategy is to solve tolerability, administration, adherence, or supply problems without creating unnecessary formulation complexity.

What is the FDA status of prednisone?

Prednisone is an FDA-approved synthetic glucocorticoid used for inflammatory, allergic, autoimmune, hematologic, respiratory, and dermatologic conditions. It is administered orally and is converted in vivo to prednisolone, the pharmacologically active metabolite.

Attribute	Prednisone
Active ingredient	Prednisone
Drug class	Systemic corticosteroid
Primary oral forms	Immediate-release tablets; delayed-release tablets; oral solutions or suspensions in selected markets
Common strengths	1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg
FDA pathway	Approved drug; multiple abbreviated new drug applications
Reference products	Historical Deltasone products; Rayos delayed-release tablets
Biosimilar pathway	Not applicable
Prescription status	Prescription-only
Core patent position	Mature active ingredient with extensive generic competition
Main commercial constraint	Low price and substitution by generic tablets

The FDA-approved prednisone market is dominated by generic immediate-release tablets. Rayos is a branded delayed-release prednisone product approved under NDA 202992. Its formulation uses delayed release to modify the timing of prednisone exposure rather than changing the active ingredient.[1]

Prednisone should be distinguished from prednisolone. Prednisone is a prodrug, while prednisolone is the active corticosteroid. This distinction affects product selection, excipient design, bioequivalence strategy, and competitive positioning.

What excipients are used in generic prednisone tablets?

Generic prednisone tablets commonly use conventional direct-compression or wet-granulation excipient systems. Public product labels identify combinations such as lactose monohydrate, corn starch, calcium stearate, magnesium stearate, povidone, hypromellose, talc, and colorants, depending on the manufacturer and strength.[2]

Representative excipient functions include:

Excipient category	Common examples	Function in prednisone tablets
Diluent	Lactose monohydrate, microcrystalline cellulose	Provides tablet mass and improves content uniformity
Binder	Povidone, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Corn starch, sodium starch glycolate, crospovidone	Promotes tablet breakup
Lubricant	Magnesium stearate, calcium stearate	Reduces tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose	Protects tablet and supports appearance
Opacifier or pigment	Titanium dioxide, iron oxides	Supports identification and color matching
Sweetener or flavor	Sucralose, sorbitol, flavors	Supports liquid and orally disintegrating formats

The lowest-cost formulation generally uses lactose or microcrystalline cellulose with starch, a lubricant, and a simple film coat. The main technical risks are low-dose content uniformity, tablet friability, punch adhesion, dissolution variability, and dose-to-dose color consistency.

Which prednisone excipient strategies have the best commercial potential?

The strongest opportunities address a specific patient or manufacturing problem.

Lactose-free prednisone tablets

Lactose-free tablets can target patients with lactose intolerance, dairy-related excipient restrictions, or institutions that prefer simplified excipient profiles. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and selected starch systems can replace lactose.

The commercial advantage is modest in standard adult tablets because many competing products already exist. The opportunity improves when the product is paired with another differentiator, such as low-dose flexibility, pediatric use, or a clean-label positioning.

Pediatric prednisone liquids

Pediatric corticosteroid administration is often limited by bitter taste, dose measurement errors, and difficulty swallowing tablets. A commercially differentiated liquid should address:

• Taste masking
• Chemical and microbiological stability
• Uniformity after shaking
• Accurate dosing across a broad concentration range
• Low-sugar or sugar-free positioning
• Preservative tolerance
• Compatibility with oral syringes and dosing cups

Useful excipient systems may include suspending agents such as xanthan gum, microcrystalline cellulose with carboxymethylcellulose, or hypromellose. Polysorbates or other wetting agents may improve dispersion where appropriate. Buffer selection must preserve prednisone stability and avoid excessive irritation.

Sugar-free products using sorbitol, glycerol, xylitol, or high-intensity sweeteners can target diabetes-conscious patients and institutional formularies. Polyols can create gastrointestinal tolerability issues, so the concentration and labeling strategy require careful control.

Orally disintegrating prednisone tablets

An orally disintegrating tablet can address swallowing difficulty, pediatric administration, and use outside conventional pharmacy settings. Mannitol-based systems are common because they provide a pleasant mouthfeel and support rapid tablet breakup. Crospovidone, sodium starch glycolate, and low-substitution hydroxypropyl cellulose can support disintegration.

The principal formulation risks are:

• Prednisone bitterness
• Tablet friability
• Moisture sensitivity
• Packaging cost
• Dose uniformity at low strengths
• Adequate mechanical strength during distribution

Aluminum-aluminum blister packaging may be necessary for a moisture-sensitive product, increasing cost relative to bottles.

Taste-masked prednisone suspension

A taste-masked suspension can create a meaningful product distinction if it provides reliable dosing and acceptable palatability. Taste masking may use polymeric coating, ion-exchange resins, flavor systems, or pH-dependent precipitation. The approach must not materially delay dissolution after administration.

A suspension product is more difficult to manufacture and register than a conventional tablet. It also introduces sedimentation, redispersibility, preservative, microbial-limit, container-closure, and in-use stability requirements.

Delayed-release prednisone

Delayed-release prednisone is the highest-value formulation segment because it can support a differentiated clinical use case and a higher price than conventional generic tablets. The Rayos product uses a delayed-release design intended to release prednisone after a lag period.[1]

An excipient strategy can include:

1. Immediate-release core tablet containing prednisone.
2. Functional polymer coating that resists release during the desired lag period.
3. Pore-forming or permeability-modifying excipients.
4. Plasticizer to control film flexibility.
5. Protective outer coat for handling and appearance.

Relevant coating materials may include methacrylic acid copolymers, hypromellose, ethylcellulose, cellulose acetate derivatives, talc, and triethyl citrate. Selection depends on the target release mechanism, pH response, coating thickness, and dissolution profile.

A delayed-release product faces a higher regulatory and patent burden. It must demonstrate reliable release timing, food-effect performance, stability, and bioequivalence or clinical comparability under the applicable FDA pathway.

What patents protect prednisone formulations?

The prednisone active ingredient is a mature compound. Broad composition-of-matter exclusivity is not the commercial barrier in the current U.S. market. The relevant protection is product-specific and can involve:

• Delayed-release architecture
• Polymer coating systems
• Release timing
• Treatment methods
• Dose regimens
• Manufacturing processes
• Particular combinations of excipients
• Device or packaging systems

Rayos established a branded delayed-release prednisone product category. Any company developing a competing delayed-release product must review current FDA Orange Book listings, issued patents, patent term adjustments, pediatric extensions, and litigation history before filing.[3]

Patent issue	Immediate-release generic	Delayed-release prednisone
Active-ingredient patent risk	Low for the mature compound	Low for the compound itself
Formulation patent risk	Usually limited	Potentially material
Method-of-use risk	Depends on labeled indication	Can be relevant to chronotherapy or regimen claims
Paragraph IV exposure	Generally low	Higher if listed patents remain enforceable
Bioequivalence complexity	Conventional oral solid	Release-profile and food-effect complexity
Commercial differentiation	Limited	Greater, but costly

A Paragraph IV challenge is most relevant when a listed formulation patent remains active and blocks an ANDA applicant. For conventional prednisone tablets, competition is generally based on ordinary ANDA approval and price. For delayed-release prednisone, patent certification and potential litigation can become central to launch timing.

When does prednisone lose exclusivity?

Prednisone has already lost broad market exclusivity in the United States. Generic immediate-release products have been available for decades, and the market contains multiple manufacturers.

The practical exclusivity timeline is:

Period	Commercial status
Initial approval era	Prednisone introduced as a systemic oral corticosteroid
Generic transition	Active ingredient and conventional tablet products became broadly generic
2012	Rayos delayed-release prednisone approved under NDA 202992
Current market	Conventional tablets are highly competitive; differentiated modified-release products remain more defensible

The key distinction is between molecule-level exclusivity and formulation-level protection. A generic company can market immediate-release prednisone without challenging a delayed-release product if the generic product does not infringe valid listed claims and meets FDA requirements.

What is the Orange Book status of prednisone?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Conventional prednisone tablets are represented by multiple abbreviated applications. Orange Book analysis should be performed at the product level because strengths, dosage forms, reference products, and listed patents can differ.[3]

The relevant regulatory categories are:

• Immediate-release tablets approved through ANDAs
• Delayed-release tablets approved under an NDA
• Product-specific patents associated with modified-release prednisone
• No biosimilar listing because prednisone is a synthetic small molecule
• No biologic interchangeability framework

An excipient change to an approved generic product may require a supplement, stability data, dissolution comparison, or other CMC documentation under FDA postapproval change rules. A new dosage form or materially different release mechanism typically requires a more substantial regulatory strategy than a composition change within an existing tablet platform.[4]

What generic entry risks exist for prednisone?

Generic entry risk is high for standard immediate-release prednisone. The active ingredient is old, manufacturing routes are established, and patients and prescribers commonly accept generic substitution.

The main risks for a new immediate-release entrant are commercial rather than legal:

• Low reimbursement
• Pharmacy benefit manager price pressure
• Established supplier relationships
• Limited switching incentive
• High competition across common strengths
• Product withdrawal risk if margins cannot support manufacturing

The most attractive entry points are less commoditized presentations:

• 1 mg and 2.5 mg dose-flexible tablets
• Pediatric liquid
• Sugar-free liquid
• Lactose-free tablets
• Orally disintegrating tablets
• Unit-dose hospital packaging
• Supply-secure products for shortage-prone strengths
• Delayed-release prednisone, subject to patent and regulatory review

Which companies are challenging prednisone products?

Generic prednisone is supplied by numerous manufacturers and labelers, including large generic companies, specialty manufacturers, and contract-manufacturing organizations. The competitive field changes frequently because marketing status, discontinuations, private-label arrangements, and shortage conditions change over time.

The most relevant competitive groups are:

1. Large generic companies selling standard tablets.
2. Specialty companies developing modified-release or patient-centric dosage forms.
3. Compounding pharmacies supplying customized liquids or capsules under applicable compounding rules.
4. Contract manufacturers providing tableting, coating, liquid, and packaging capacity.

Competition against Rayos is more likely to involve a formulation-specific product than a conventional prednisone tablet. A company attempting a delayed-release launch must evaluate infringement, Paragraph IV exposure, settlement risk, and potential launch dates before committing clinical and manufacturing resources.

What manufacturing and intellectual property barriers affect prednisone?

Immediate-release prednisone has relatively low manufacturing barriers. A standard tablet facility can produce the product if it has suitable containment, blending, compression, coating, analytical, and stability capabilities.

Important process controls include:

• Uniform distribution of low-dose prednisone
• Control of blend segregation
• Lubrication time
• Tablet hardness and friability
• Dissolution across all strengths
• Cleaning validation for corticosteroid residues
• Cross-contamination controls
• Packaging moisture protection

Prednisone is pharmacologically potent at low doses, so containment and cleaning requirements can affect plant economics even though the molecule is inexpensive.

Modified-release products create higher barriers. The manufacturer must control coating weight gain, spray rate, inlet temperature, exhaust conditions, polymer dispersion, curing, and release-profile variability. Scale-up can change the lag time and dissolution curve even when the formulation composition remains unchanged.

The most defensible IP position usually comes from a combined formulation and process platform rather than a simple excipient substitution. Claims directed only to routine excipient choices may face validity and obviousness challenges if the formulation does not produce an unexpected release, stability, or bioavailability result.

How does prednisone compare with prednisolone?

Prednisone and prednisolone compete within the same corticosteroid treatment market but have different formulation implications.

Issue	Prednisone	Prednisolone
Pharmacology	Prodrug converted to prednisolone	Active drug
Common patient use	Broad systemic corticosteroid therapy	Common in pediatrics and patients requiring active drug
Oral liquids	Commercial opportunity exists	Often stronger because liquid use is established
Taste challenge	Significant	Significant
Conventional tablet competition	Very high	Very high
Modified-release opportunity	Demonstrated by Rayos	Less defined in common U.S. products
Biosimilar relevance	None	None

Prednisolone may be preferred where predictable active-drug exposure is important, particularly in pediatric liquid therapy. Prednisone may offer a stronger opportunity for differentiated delayed release because a branded product has established that formulation category.

What licensing deals and settlement agreements affect prednisone?

Prednisone has limited licensing value at the molecule level because conventional tablets are generic. Licensing opportunities are more likely to concern:

• Delayed-release coating technology
• Taste-masking platforms
• Pediatric liquid technology
• Contract manufacturing capacity
• Hospital unit-dose packaging
• Geographic commercialization rights
• Formulation patents or know-how

Settlement agreements are most relevant to a generic applicant challenging patents associated with a branded delayed-release product. A settlement can define an authorized generic arrangement, a licensed launch date, supply rights, or restrictions on commercialization. Publicly available litigation and FDA patent records should be reviewed for the specific product and applicant before relying on any launch assumption.[3,5]

What revenue exposure exists in the prednisone market?

Standard prednisone tablets generally have low revenue per prescription and high volume. Revenue exposure is concentrated in product portfolios rather than in a single premium brand.

Product strategy	Revenue potential	Margin potential	Development risk
Standard immediate-release tablet	Low	Low	Low
Multiple-strength generic platform	Low to moderate	Low	Low
Lactose-free tablet	Moderate	Moderate	Low to moderate
Pediatric liquid	Moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate	Moderate to high	Moderate
Delayed-release tablet	Higher	Higher	High
Hospital unit-dose product	Moderate	Moderate	Moderate
Specialty packaging or supply-secure product	Moderate	Moderate	Low to moderate

The commercial case improves when the formulation earns formulary preference, reduces administration errors, addresses a documented shortage, or supports a pediatric or institutional niche. A premium price without a clear administration or clinical benefit is unlikely to survive generic substitution.

What is the strongest prednisone excipient strategy?

For a low-risk generic launch, the strongest approach is a robust immediate-release tablet using a conventional, broadly accepted excipient system with optional lactose-free variants. The product should prioritize content uniformity, rapid disintegration, dissolution consistency, manufacturability, and low packaging cost.

For a differentiated product, the strongest near-term opportunities are:

1. Pediatric, sugar-free, taste-masked suspension.
2. Orally disintegrating tablet with low friability and acceptable taste.
3. Lactose-free, dose-flexible tablet platform.
4. Delayed-release tablet supported by a clear chronotherapy rationale and freedom-to-operate analysis.

A delayed-release strategy has the greatest potential value but also the highest patent, development, and manufacturing risk. An excipient portfolio should be designed around the target product profile rather than assembled from generic tablet ingredients.

Key Takeaways

• Prednisone is a mature small-molecule corticosteroid with extensive immediate-release generic competition.
• The active ingredient has limited current exclusivity value; formulation and method-of-use rights are more relevant.
• Conventional tablets offer low legal risk but limited margin and weak differentiation.
• Pediatric liquids, orally disintegrating tablets, lactose-free products, and unit-dose formats provide clearer commercial niches.
• Delayed-release prednisone has the strongest differentiation potential but requires detailed Orange Book, patent, dissolution, and bioequivalence analysis.
• Biosimilar risk does not apply because prednisone is a synthetic small molecule.
• Manufacturing barriers are modest for immediate-release tablets and materially higher for polymer-coated delayed-release products.
• The best excipient strategy combines a specific administration benefit with low manufacturing complexity and defensible product positioning.

FAQs About Prednisone Excipient Strategy

Can prednisone tablets be made without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or other suitable diluents. The formulation must maintain content uniformity, hardness, disintegration, dissolution, and stability.

Is prednisone suitable for an oral suspension?

Yes. Prednisone can be developed as an oral suspension, but the product requires control of taste, sedimentation, redispersibility, microbial quality, preservative performance, and dose uniformity.

Does prednisone have biosimilar competition?

No. Prednisone is a synthetic small molecule and is regulated through generic drug pathways rather than the FDA biosimilar pathway.

Is delayed-release prednisone protected by patents?

Potentially. Delayed-release prednisone can be protected by product-specific formulation, coating, release-profile, method-of-use, or manufacturing patents. The applicable claims must be reviewed in the current FDA Orange Book and relevant patent records.

What prednisone dosage form has the best commercial opportunity?

A pediatric taste-masked liquid or a delayed-release tablet generally offers more differentiation than a conventional immediate-release tablet. The liquid has lower patent risk, while the delayed-release tablet may offer higher pricing but greater regulatory and litigation exposure.

References

1. U.S. Food and Drug Administration. (2012). RAYOS (prednisone) delayed-release tablets, prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Prednisone tablet labels and inactive ingredient listings.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2014). Changes to an approved NDA or ANDA: Guidance for industry.
5. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records.